Hematopoietic Cell Patents (Class 424/153.1)
-
Patent number: 7695715Abstract: The invention concerns novel DNA and amino acid sequences of monoclonal antibodies (mAbs) raised against lymphoblastoid cells and peptides to which the mAbs bind to. The invention also concerns diagnostic assays using said antibodies or peptides for detecting individuals with a high probability of having a malignant disease and, at times, for detecting an individual having a specific malignant disease. The invention further concerns pharmaceutical compositions comprising the mAbs or peptides of the invention for use in the treatment of various malignant diseases as well as methods for the treatment of malignant diseases using the mAbs or peptides of the invention.Type: GrantFiled: December 23, 2005Date of Patent: April 13, 2010Assignee: Mor Research Applications Ltd.Inventors: Britta Hardy, Abraham Novogrodsky
-
Patent number: 7695716Abstract: Methods of treating cancer and autoimmune and inflammatory diseases are provided.Type: GrantFiled: April 11, 2008Date of Patent: April 13, 2010Assignee: Seattle Genetics, Inc.Inventors: Jonathan G. Drachman, May Kung Sutherland, Eric Sievers, Grant Risdon, Alan Wahl, Tim Lewis
-
Patent number: 7682612Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: November 9, 1999Date of Patent: March 23, 2010Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 7682614Abstract: Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example ?-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.Type: GrantFiled: November 2, 2005Date of Patent: March 23, 2010Assignee: The Board Of Trustees Of The Leland Stanford Junior UniversityInventors: Samuel Strober, Everett Hurteau Meyer, Dale T. Umetsu
-
Patent number: 7666422Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: January 20, 2009Date of Patent: February 23, 2010Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 7666421Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: December 5, 2005Date of Patent: February 23, 2010Assignee: Genetics Institute, LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Patent number: 7655230Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.Type: GrantFiled: April 21, 2008Date of Patent: February 2, 2010Assignee: Genentech, Inc.Inventors: Martin M. Bednar, Cordell E. Gross, Linda J. Gross, legal representative, G. Roger Thomas
-
Patent number: 7651678Abstract: Primitive or progenitor hematologic cancer cells have been implicated in the early stages and development of leukemia and malignant lymphoproliferative disorders, including acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Interleukin-3 receptor alpha chain (IL-3R? or CD123) is strongly expressed on progenitor hematologic cancer cells, but is virtually undetectable on normal bone marrow cells. The present invention provides methods of impairing progenitor hematologic cancer (e.g., leukemia and lymphomic) cells by selectively targeting cells expressing CD123. These methods are useful in the detection and treatment of leukemias and malignant lymphoproliferative disorders. Also provided are compounds useful for selectively binding to CD123 and impairing progenitor hematologic cancer cells. These compounds may include cytotoxic moieites such as, for example, radioisotopes or chemotherapeutics.Type: GrantFiled: April 23, 2004Date of Patent: January 26, 2010Assignee: University of Kentucky Research FoundationInventor: Craig Jordan
-
Patent number: 7642045Abstract: A novel cytosolic 58 kd phosphoprotein induced during bone marrow stem cell (BM) differentiation into dendritic cells (DC) during in vitro cultivation with the cytokine GM-CSF by addition of antisera to an 82 kd BM cell surface protein generating cultivatable dendritic progenitor cells (DP). Genes, methods for preparing them as well as early DP have been provided. Potential uses/advantages lie in the study of BM differentiation and innate immunity due to stimulatory/inhibitory DC, contribution of (BM) and DP to inflammation during infection and carcinogenesis, tumor promotion/regression, identification of BM-derived blood cells, T-cell activation/regulation/tolerance and inflammation.Type: GrantFiled: November 18, 2005Date of Patent: January 5, 2010Inventor: Swapan K. Ghosh
-
Publication number: 20090311268Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.Type: ApplicationFiled: April 8, 2009Publication date: December 17, 2009Applicant: Pangenetics BVInventors: David Thomas, Mark de Boer, Pieter C.J.M. Res, Peter J. Simons
-
Patent number: 7618633Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: September 25, 2007Date of Patent: November 17, 2009Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 7615219Abstract: The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).Type: GrantFiled: January 16, 2004Date of Patent: November 10, 2009Assignee: Life Sciences Research Partners VZWInventors: Kathleen Freson, Chris Van Geet, Marc Hoylaerts
-
Patent number: 7611707Abstract: The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.Type: GrantFiled: April 26, 2005Date of Patent: November 3, 2009Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Narendra Nath Tandon, Yutaka Matsumoto, Hisao Takizawa, Keiji Okuyama
-
Patent number: 7611708Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: October 6, 2008Date of Patent: November 3, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7604800Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: May 10, 2005Date of Patent: October 20, 2009Assignee: AbGenomics Coöperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 7592006Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.Type: GrantFiled: April 7, 1998Date of Patent: September 22, 2009Assignee: Université Catholique de LouvainInventors: Herve Bazin, Dominique Latinne
-
Patent number: 7592007Abstract: Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed.Type: GrantFiled: December 9, 2003Date of Patent: September 22, 2009Assignees: Dana-Farber Cancer Institute, Inc., Genetics Institute, LLCInventors: John G. Gribben, Gordon J. Freeman, Lee M. Nadler, Paul Rennert, Cindy L. Jellis, Edward Greenfield, Gary S. Gray
-
Patent number: 7563445Abstract: Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab?)2 and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.Type: GrantFiled: August 26, 2002Date of Patent: July 21, 2009Assignee: Keygene N.V.Inventors: Cornelis J. M. Melief, Stephen P. Schoenberger, Rienk Offringa, Rene Toes
-
Patent number: 7563443Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: April 8, 2005Date of Patent: July 21, 2009Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7563441Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: April 8, 2005Date of Patent: July 21, 2009Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: 7563442Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: August 26, 2005Date of Patent: July 21, 2009Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20090162374Abstract: The present invention provides a method of detecting an immune response in a mammalian subject by (a) withdrawing blood or a blood fraction containing immune cells from the subject, (b) contacting the blood with an antibody that specifically binds to the cell surface HLA-F histocompatibility protein of activated mammalian immune cells and then (c) detecting the presence or absence of binding of immune cells to the antibody, wherein the presence of binding indicates the presence of an immune response in the subject.Type: ApplicationFiled: August 31, 2006Publication date: June 25, 2009Inventors: Daniel E. Geraghty, Ni Lee
-
Publication number: 20090155273Abstract: Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.Type: ApplicationFiled: November 11, 2008Publication date: June 18, 2009Applicant: Japan Tobacco, Inc.Inventor: Mamoru Watanabe
-
Patent number: 7547438Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.Type: GrantFiled: December 20, 2006Date of Patent: June 16, 2009Assignee: Pangenetics BVInventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simone
-
Publication number: 20090136516Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.Type: ApplicationFiled: May 7, 2004Publication date: May 28, 2009Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
-
Patent number: 7537763Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.Type: GrantFiled: December 5, 2006Date of Patent: May 26, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Toshifumi Mikayama, Hitoshi Yoshida, Walker R. Force, Xingjie Chen, Nobuaki Takahashi
-
Patent number: 7531175Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: GrantFiled: November 12, 2004Date of Patent: May 12, 2009Assignee: Genetics Institute LLCInventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
-
Publication number: 20090117128Abstract: The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet alloantigen using said antibody, a method for the production of said antibody, a pharmaceutical composition comprising said antibody, and a kit containing said antibody.Type: ApplicationFiled: June 13, 2008Publication date: May 7, 2009Applicant: Stiftung fur DiagnostischeInventors: Dominique Rigal, Jean Jacques Pin, Yves Merieux
-
Patent number: 7510712Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: August 17, 2007Date of Patent: March 31, 2009Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7510711Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: April 8, 2005Date of Patent: March 31, 2009Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 7510713Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: August 17, 2007Date of Patent: March 31, 2009Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7501124Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.Type: GrantFiled: October 7, 2004Date of Patent: March 10, 2009Assignees: Trustees of Dartmouth College, University of MassachusettsInventors: Randolph J. Noelle, Fiona H. Durie, David C. Parker, Michael C. Appel, Nancy E. Phillips, John P. Mordes, Dale L. Grenier, Aldo A. Rossini
-
Patent number: 7501496Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: GrantFiled: September 16, 2005Date of Patent: March 10, 2009Assignee: Roche Palo Alto LLCInventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Patent number: 7498032Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: May 14, 2004Date of Patent: March 3, 2009Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Publication number: 20090047290Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.Type: ApplicationFiled: April 11, 2008Publication date: February 19, 2009Applicant: CANADIAN BLOOD SERVICESInventors: Heyu Ni, Guangheng Zhu
-
Patent number: 7491393Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: August 17, 2007Date of Patent: February 17, 2009Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Patent number: 7482003Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: November 29, 2006Date of Patent: January 27, 2009Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 7476385Abstract: Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.Type: GrantFiled: January 4, 2005Date of Patent: January 13, 2009Assignee: Trustees of Darthmouth CollegeInventors: Randolph J. Noelle, Teresa M. Foy
-
Publication number: 20080317745Abstract: The present invention relates to methods and compositions for the diagnosis, treatment, management, or prevention of plasma cell disorders, including systemic light-chain amyloidosis (AL) and multiple myeloma (MM). In particular, the invention encompasses the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof, or compounds or agents that bind to CD32B and modulate CD32B activity in the plasma cells of mammals. The invention also encompasses the use of anti-CD32B antibodies, analogs, derivatives or fragments thereof, or CD32B binding compounds or agents in combination with or in addition to other cancer therapies for the treatment, prevention, management, or amelioration of a plasma cell disorder characterized by the expression of CD32B, or one or more symptoms thereof.Type: ApplicationFiled: September 17, 2007Publication date: December 25, 2008Inventors: Adam M. Boruchov, Raymond L. Comenzo
-
Publication number: 20080317749Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.Type: ApplicationFiled: September 2, 2008Publication date: December 25, 2008Applicant: SCHERING CORPORATIONInventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
-
Use of K -252a and Kinase Inhibitors for the Prevention or Treatment of Hmgb1-Associated Pathologies
Publication number: 20080317809Abstract: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis.Type: ApplicationFiled: July 29, 2005Publication date: December 25, 2008Inventors: Silvano Fumero, Francesco P. Pilato, Domenico Barone, Luisa Bertarione Ravarossa, Valentina Mainero, Traversa Silvio -
Patent number: 7465464Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: January 5, 2005Date of Patent: December 16, 2008Assignee: Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 7462352Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.Type: GrantFiled: June 1, 2006Date of Patent: December 9, 2008Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7445798Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: August 11, 2003Date of Patent: November 4, 2008Assignee: Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 7445781Abstract: The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.Type: GrantFiled: May 10, 2005Date of Patent: November 4, 2008Assignee: Trustees of Dartmouth CollegeInventor: Randolph J. Noelle
-
Patent number: 7445780Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: August 31, 2007Date of Patent: November 4, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Publication number: 20080267973Abstract: The present invention relates to agonists, antagonists, and other molecules that specifically bind SIGLEC-6 on mast cells, their use in the treatment of asthma and other SIGLEC-6 mediated diseases or disorders, methods of diagnosing such diseases or disorders, and methods of screening for candidate compounds capable of modulating SIGLEC-6 activity in mast cells. The present invention also relates to the diagnosis and treatment of B-cell related disorders using compounds that bind and/or modulate SIGLEC-6.Type: ApplicationFiled: June 9, 2005Publication date: October 30, 2008Inventors: Shen-Wu Wang, Guanghu Hu, Zhengbin Yao
-
Patent number: 7429647Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.Type: GrantFiled: January 18, 2006Date of Patent: September 30, 2008Inventors: Andreas Morell, Martin Imboden, Beda Statler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
-
Patent number: 7422744Abstract: The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to ?v?3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of ?v?3. The method consists of contacting ?v?3 with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to ?v?3.Type: GrantFiled: May 30, 2003Date of Patent: September 9, 2008Assignee: Applied Molecular Evolution, Inc.Inventors: William D Huse, Scott M Glaser
-
Patent number: RE40811Abstract: The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.Type: GrantFiled: November 15, 1993Date of Patent: June 30, 2009Assignee: Board of Regents of the University of WashingtonInventor: Thalia Papayannopoulou